Improved water supply infrastructure to reduce acute diarrhoeal diseases and cholera in Uvira, Democratic Republic of the Congo: Results and lessons learned from a pragmatic trial

by Karin Gallandat, Amy Macdougall, Aurélie Jeandron, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Espoir Bwenge Malembaka, Andrew S. Azman, Didier Bompangue, Simon Cousens, Elizabeth Allen, Oliver Cumming

Safely managed drinking water is critical to prevent diarrhoeal diseases, including cholera, but evidence on the effectiveness of piped water supply in reducing these diseases in low-income and complex emergency settings remains scarce.

We conducted a trial of water supply infrastructure improvements in Uvira (DRC). Our primary objective was to estimate the relationship between a composite index of water service quality and the monthly number of suspected cholera cases admitted to treatment facilities and, as a secondary analysis, the number of cases confirmed by rapid diagnostic tests. Other exposures included the quantity of supplied water and service continuity. We used Poisson generalised linear models with generalised estimating equations to estimate incidence rate ratios.

Associations between suspected cholera incidence and water service quality (RR 0·86, 95% CI 0·73–1·01), quantity (RR 0·80, 95% CI 0·62–1·02) and continuity (RR 0·81, 95% CI 0·77–0·86) were estimated. The magnitudes of the associations were similar between confirmed cholera incidence and water service quality (RR 0·84, 95% CI 0·73–0·97), quantity (RR 0·76, 95% CI 0·61–0·94) and continuity (RR 0·75, 95% CI 0·69–0·81). These results suggest that an additional 5 L/user/day or 1.2 hour per day of water production could reduce confirmed cholera by 24% (95% CI 6–39%) and 25% (95% CI 19–31%), respectively.

Ensuring a sufficient and continuous piped water supply may substantially reduce the burden of endemic cholera and diarrhoeal diseases but evaluating this rigorously is challenging. Pragmatic strategies are needed for public health research on complex interventions in protracted emergency settings.

The trial is registered in ClinicalTrials.gov ID NCT02928341. https://classic.clinicaltrials.gov/ct2/show/NCT02928341.